45 results on '"Díez-Campelo M"'
Search Results
2. P118 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
3. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
4. P074 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS
5. P075 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW CYTOKINES AND CHEMOKINES CONCENTRATIONS IN MYELODISPLASTIC NEOPLASMS
6. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
7. P041 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
8. O10 - CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES
9. LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
10. P31 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: PHENOTYPE AND GENOTYPE OF NATURAL KILLERS IN MYELODISPLASITIC SYNDROME
11. P36 - Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS MAY ENHANCE RESIDUAL HEALTHY HAEMATOPOIESIS IN LOW-RISK MDS PATIENTS
12. P30 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: RELATION BETWEEN INMUNE CELL POPULATIONS AND MALIGNANT CLONE MUTATIONAL STATUS IN MYELODYSPLASTIC SYNDROMES
13. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
14. O20 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCORPORATION OF COHESIN MUTATIONAL DATA INTO CURRENT IPSS-R CLASSIFICATION REFINES THE PROGNOSTIC STRATIFICATION OF VERY LOW/LOW-RISK MYELODYSPLASTIC SYNDROMES
15. CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial
16. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)
17. P39 The Humanistic Burden of Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes on Patients and Caregivers: Qualitative Research Findings
18. Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia
19. 41 - Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation
20. 261 - What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools
21. 238 - Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance
22. 235 - The Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts can be Improved by Considering Bone Marrow Blasts from Nonerythroid Cells
23. 208 - Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML
24. 196 - Mutational Status of Mesenchymal Stem Cell in Myelodysplastic Syndromes Patients
25. 163 - DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia
26. 81 - Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence
27. 87 - Mutational and Clonal Dynamics During Progression from MDS to SAML by Whole-Exome and Targeted-Deep Sequencing
28. 10 - Mutational Signature and Clonal Architecture of Low Risk Myelodysplastic Syndromes with Del(5Q)
29. 261 ERYTHROLEUKEMIA APPEARS TO BE A CONTINUUM OF MDS WITH ERYTHROID HYPERPLASIA AND SHARES OUTCOME AND CYTOGENETIC FEATURES WITH RAEB-1 WITH ≥50% ERYTHROPOIESIS
30. 244 MYELOFIBROSIS (MF) AS A PROGNOSTIC TOOL FOR OVERALL SURVIVAL IN MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE EVALUATION INCLUDING MUTATIONAL ANALYSIS BY NEXT GENERATION SEQUENCING (NGS)
31. 171 A TWO-STEP APPROACH FOR THE ANALYSIS OF SPLICING GENES IN MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS
32. 118 A PHASE 2 STUDY OF AZACITIDINE AND EPOETIN-BETA IN UNTREATED RBC-TRANSFUSION DEPENDENT LOWER-RISK MDS PATIENTS
33. 29 MICROVESICLES/EXOSOMES DERIVED FROM BONE MARROW MESENCHYMAL STROMAL CELLS (MSC) ARE INVOLVED IN THE INTERCELLULAR COMMUNICATION BETWEEN HEMATOPOIETIC CELLS AND BM MICROENVIRONMENT IN MDS PATIENTS
34. P-234 Mesenchymal stromal cells from MDS with 5q- show different genetic and epigenetic changes compared to those from other low-risk MDS
35. P-054 Application of array-based karyotyping as a complementary tool in the diagnosis of myelodysplastic syndromes and related myeloid neoplasms
36. 315 Prognostic impact of performance status and comorbidity on the overall survival of patients with myelodysplastic syndromes: A prospective evaluation
37. 235 An integrative analysis of methylation and gene expression profiling in low-risk myelodysplastic syndromes (MDS)
38. 258 Down-regulation of DICER1, DROSHA and microRNAs in MSC from MDS compared to healthy controls
39. 108 SNP-A karyotyping in primary myelodysplastic syndromes with unsuccessful routine cytogenetic testing
40. 78 A small subset of mesenchymal stem cells from MDS patients harbour the cytogenetic abnormality of haematopoietic cells
41. 64 A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion
42. 65 Simultaneous analysis of the expression of 14 genes with individual prognostic value in patients with MDS at diagnosis
43. Pentostatin in refractory acute and chronic GVHD. A single center experience
44. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft versus host disease (GVHD)
45. Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.